A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT07579234 · RECRUITING
Trial details
- NCT number
- NCT07579234
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-25
- Primary completion
- 2029-01-25
- Enrollment
- 261
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.